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Abstract
Peptides containing the RGD sequence are under continuous investigation given their ability to control cell adhesion and
apoptosis. Since small peptides are quickly metabolized and degraded in vivo, developing analogs resistant to serum-
induced degradation is a challenging task. RGD analogs developed so far are known as molecules mostly inhibiting cell
adhesion; this feature may reduce cell proliferation and tumor development but may not induce regression of tumors or
metastases already formed. In the current study, carried out in melanoma in vitro and in vivo models, we show that RAM, an
RGD-non-peptide Analog-Molecule, strongly inhibits cells adhesion onto plastic, vitronectin, fibronectin, laminin and von
Willebrand Factor while it does not inhibit cell adhesion onto collagen IV, similarly to the RGDS template peptide. It also
strongly inhibits in vitro cell proliferation, migration and DNA-synthesis, increases melanoma cells apoptosis and reduces
survivin expression. All such effects were observed in collagen IV seeded cells, therefore are most likely independent from
the anti adhesive properties. Further, RAM is more stable than the template RGDS; in fact it maintains its anti-proliferation
and anti-adhesion effects after long serum exposure while RGDS almost completely loses its effects upon serum exposure.
In a mouse metastatic melanoma in vivo model, increasing doses of RAM significantly reduce up to about 80% lung
metastases development, while comparable doses of RGDS are less potent. In conclusion these data show that RAM is a
potent inhibitor of melanoma growth in vitro, strongly reduces melanoma metastases development in vivo and represents a
novel candidate for further in vivo investigations in the cancer treatment field.
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Introduction
Cell adhesion to cells and to the extracellular matrix controls
different cellular functions, including survival, proliferation,
migration and apoptosis [1,2] and directly affects tissue plasticity
and remodeling under both physiological and pathological
conditions. The RGD (Arginine-Glycine-Aspartic acid) motif
occurs in several extracellular matrix proteins; it is recognized
by membrane-bound adhesion molecules and therefore plays a key
role as cell adhesion mediator [2]. Peptides containing this motif
show potent anti adhesion effects, since they compete for the
integrin-matrix interaction and show anti-proliferative, anti-
chemotactic and pro-apoptotic effects. Moreover, antibodies
neutralizing avb3 and a5b1 block integrin–mediated cell adhesion
by antagonizing the RGD motif and completely inhibit tube
formation in fibrin matrices [3]. Similarly, disintegrins molecules
containing the RGD motif are known to block FGF-2-induced
angiogenesis and B16F10 melanoma lung metastasis development
in mice [4]. For the same reasons, molecules containing RGD
motif immobilized onto appropriate matrices have pro-adhesive
effects and RGD analogs may then elicit selective cellular
responses such as wound healing, cell adhesion and migration
[5,6,7]. Adhesive properties of RGD motif are been exploited for
tumor imaging, targeting and radio treatment [8,9,10,11,12].
Small peptides have short circulation time since they are quickly
proteolysed and metabolized in vivo. Peptides containing the RGD
motif act via a competition mechanism [13], therefore high doses
are usually required to reach in vivo effects, limiting the
pharmacological use of RGD peptides and justifying the large
interest to develop non-peptidic analogs with higher potency
[14,15,16]. In order to overcome, at least in part, the issue
regarding stability in serum, sequence modifications such as
duplication and circularization [17,18], synthesis of non peptidic
analogs and liposomalization [19,20,21,22] have been carried to
enhance the stability and retention in the bloodstream.
We have previously demonstrated that RGDS peptide has
additional effects not directly related to its anti adhesion activity.
In fact we found that it is internalized into human endothelial cells
and recognizes intracellular targets such as caspase-3, caspase-8
and caspase-9, leading to apoptosis most likely by an integrin-
independent mechanism [23]. More recently we demonstrated
that RGDS is internalized in melanoma cells, inhibiting their
growth and inducing their apoptotic death with a mechanism
independent of the extracellular anti adhesive activity [24].
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Authors [23,25,26], such data indicate intracellular activity of
RGDS-containing peptides highlighting novel pharmacological
applications and suggesting novel intracellular targets.
We have previously shown that a novel RGDS analog named
RAM (RGD-non-peptide Analog-Molecule) lacking peptidic
bonds to overcome proteolytic degradation, mimicked the pro-
apoptotic effects and the adhesive properties of RGDS on
endothelial cells and showed potent anti angiogenesis activity in
vivo [27]. Anti angiogenic and pro apoptotic molecules may have
interesting applications in melanoma treatment and the previously
demonstrated intracellular targets of RGDS opened novel fields of
investigation; we then investigated RAM in a melanoma
experimental setting and show in the present study that RAM
exerts potent biological effects independently form the anti
adhesive properties, is resistant to serum-induced loss-of-activity,
and strongly inhibits progression of lung metastases in an in vivo
melanoma mouse model.
Results
Effect of RGDS and RAM on SK-MEL-110 adhesion
RAM was designed as a RGDS analog; its molecular structure is
reported in Figure S1; in a previously published report we
characterized RAM anti angiogenic activity in vitro and in vivo [27].
We and Others previously demonstrated that cell adhesion on
collagen IV is RGD-independent [27,28,29]; as preliminary data
necessary for the following experiments, we investigated the
adhesion effects of RGDS onto SK-MEL-110 melanoma cells;
Figure 1 shows that both RGDS and RAM inhibit adhesion of
SK-MEL-110 seeded onto plastic, vitronectin, fibronectin, laminin
and von Willebrand Factor in a dose-dependent way, with
comparable potency and IC50 values, while they both lack
relevant anti adhesion action onto collagen IV-seeded cells. We
therefore concluded that RAM mimics RGDS anti adhesive as
well as non-anti adhesive properties in melanoma cells. The
adhesion-independent effects of RGDS and RAM were then
investigated on collagen-IV seeded melanoma cells.
RGDS and RAM effects on proliferation and migration of
melanoma cells
It is known that RGD peptides or RGD analogs exert anti
proliferation and pro apoptotic effects by detaching cells from
extracellular matrix, resulting in a caspase-dependent apoptosis
(anoikis) [2,19]. Under our experimental conditions, RGDS and
RAM inhibited with similar potency proliferation of melanoma
cells seeded onto plastic after 24 h incubation both in the absence
and in the presence of serum (Figure 2A and B). Such effects most
likely relate to the strong anti adhesive effect shown by RGDS and
RAM onto plastic-seeded cells (Figure 1A). However, Figure 2C
shows that both RGDS and RAM markedly reduced serum-
Figure 1. RGDS and RAM effect on melanoma cell adhesion. RGDS and RAM show relevant anti adhesive activity on cells seeded onto plastic
(A), vitronectin 50 mg/ml (B), fibronectin 10 mg/ml (C), laminin 50 mg/ml (D) and von Willebrand Factor 50 mg/ml (E), while they do not show
significant anti adhesive effects on collagen IV 50 mg/ml (F). The adhesion assay was carried out in the presence of 10% FCS and serial dilutions of
RGDS or RAM. Cell adhesion was then quantified as optical density at 595 nm and was expressed as OD. These experiments were carried out three
times in duplicate; mean 6 S.D. is reported.
doi:10.1371/journal.pone.0025352.g001
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experimental conditions where RGDS and RAM do not exert
marked anti adhesive properties (see Figure 1F); under such
conditions RGDS weakly but significantly inhibited FCS-induced
proliferation of SK-MEL-110, while RAM showed strong and
significant anti proliferation effects (Figure 2D); interestingly,
RAM maintained a strong anti-proliferative effect on a different
human melanoma cell line (SK-MEL-28), while the weak effect of
RGDS was completely lost (Figure S2). Additional experiments
indicated that RGDS and RAM significantly inhibit FGF-2-
induced proliferation of collagen IV–seeded melanoma cells
(46616% and 53614% inhibition, respectively, p,0.005)
(Figure 3A), further demonstrating that RAM and RGDS show
potent anti-mitogenic effect un-related to their anti adhesive
action. Representative fields of such anti-proliferative action are
reported in Figure 3B.
To analyze cell distribution in sub-G1-phase, melanoma cells
were treated with RGDS or RAM for 48 h and stained with
propidium iodide. Sub-G1 phase, considered as a marker of cell
apoptosis, in the presence of FGF-2 was significantly increased
(from 4% to 13.2% and to 9.8%) by RGDS or RAM treatment,
respectively, in collagen IV -seeded cells, indicating pro-apoptotic
properties most likely un-related to the anti adhesive action
(Figure 3C). This pro-apoptotic effect was not present at earlier
timepoint (i.e. 24 h incubation).
Pro apoptotic effect in the presence of FGF-2 was confirmed by
western blotting analysis investigating pro-caspase 3 cleavage.
Both RGDS and RAM treatment reduced expression of caspase 3
inactive precursor (32 kDa) (Figure 4A). They also markedly
reduced the expression of survivin, a member of the Inhibitor of
Apoptosis Protein (IAP) selectively expressed during development
and in proliferating cells and cancer cells [24].
The pro apoptotic effect was also quantified by TUNEL
staining and was observed in cells treated with FGF-2 in the
presence of RGDS or RAM (23.5% and 21.0% of total nuclei,
respectively) while it was almost absent in FGF-2-only treated cells
(1.3% of total nuclei) (Figure 4B).
All together figures 1 to 4 demonstrate with different
approaches that RAM is a good functional analog of RGDS,
and shows marked effects onto collagen-IV seeded melanoma
cells, most likely unrelated to the anti adhesion activity.
Stability test
We have previously shown that upon 24 h incubation in 100%
FCS, RGDS completely lacks anti adhesive effect onto HUVEC,
while RAM maintains the anti adhesive action similar to the fresh
RAM molecule [27,30]. Hence, in the present study we
investigated whether the observed anti proliferation activity of
RAM and RGDS onto melanoma cells is affected by 24 h pre-
incubation in 100% FCS. ‘‘Aged’’ RAM (i.e., RAM kept in FCS
100% for 24 h at 37uC) inhibited SK-MEL-110 cells proliferation
seeded onto plastic as much as the fresh molecule, while ‘‘aged’’
RGDS (i.e. incubated at 37uC for the same time) totally lost the
anti proliferation effect compared to fresh RGDS (Figure 5A top).
Representative images of treated cells are reported in Figure 5A
(bottom).
To further investigate stability in the presence of serum, RGDS
and RAM were pre-incubated in 100% FCS for increasing time
points (0.5 h, 1 h, 24 h and 48 h) at 37uC and were then used in
adhesion assays. Figure 5B shows that ‘‘aged’’ RAM maintained the
Figure 2. RGDS and RAM effect on proliferation and migration. RGDS and RAM show anti proliferation/anti migration effects onto plastic-
and onto collagen IV seeded SK-MEL-110 cells. Proliferation of human melanoma cells seeded onto plastic was evaluated in the presence of RGDS and
RAM (250–500 mg/ml) after 24 h treatment. RGDS and RAM significantly reduced melanoma cells proliferation either in the absence (A) and in the
presence of serum (B) (* p,0.05) likely with an anti adhesive mechanism. (C) Serum-induced melanoma cells invasion through collagen IV (10 mg/ml)
after 4 h incubation at 37uC was inhibited by RGDS and RAM (500 mg/ml) (* p,0.05) to a similar extent, likely with a non-anti adhesive mechanism.
Forty-eight hours proliferation was evaluated onto collagen IV. RAM significantly inhibited cell growth under these conditions, while RGDS was less
active. All proliferation and migration experiments were performed four times in duplicate and mean 6 S.D. is reported.
doi:10.1371/journal.pone.0025352.g002
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lost large part of its anti adhesive effect after 24 h and 48 h
incubation in serum.
To confirm that RAM is more potent and more stable than
RGDS in the presence of serum-induced degradation, RGDS,
RAM and the control cyclo-RGDS (a known RGDS analog with
anti adhesion activity [31]), were kept 24 h in 100% serum, to
allow serum-induced degradation. Proliferation was then mea-
sured in melanoma cells seeded onto collagen IV and treated with
the RGDS or RAM or cyclo-RGDS. Such conditions investigated
anti proliferation properties independent form the anti adhesive
actions, upon serum-induced degradation. RAM strongly inhib-
ited proliferation (about 50%), significantly more than RGDS
(about 35%) (Figure 6A), while the control cyclo-RGDS, known
anti adhesive analog of RGDS, was completely inactive, further
suggesting that such anti proliferation effect is un-related to the
anti adhesion action. RAM was also significantly more potent than
RGDS either in inhibiting BrdU incorporation (Figure 6B) and by
increasing sub-G1 phase (Figure 6C), indicating that RAM
achieves its anti proliferation effect by increasing apoptosis and
reducing DNA synthesis. Elucidating mechanisms underlying the
weak residual anti proliferation effect of RGDS upon FCS-
induced degradation, observed in Figures 2A, 5B and 6A requires
further investigation and quantitative assays.
Other experiments indicate that RAM and RGDS action does
not involve G2/M checkpoints regulation. In fact upon nocoda-
zole synchronization, neither RAM nor RGDS affect cell cycle
distribution.
All such data indicate that RAM is significantly more potent
that RGDS in collagen IV– seeded melanoma cells, in
experimental conditions mimicking the serum-dependent degra-
dation, suggesting that RAM may represent a suitable candidate
for further in vivo investigations.
In vivo experiments
To investigate in vivo effects in a mouse model, we first tested in
vitro the RGDS and RAM (500 mg/ml) effects on FCS-induced
proliferation in a mouse melanoma cell line (B16F10) seeded on
Figure 3. RGDS and RAM inhibit SK-MEL-110 proliferation and increase apoptosis with an adhesion-independent mechanism. (A)
FGF-2 (10 ng/ml)-induced SK-MEL-110 proliferation on collagen IV (50 mg/ml) was evaluated after 48 h treatment in the presence of RGDS or RAM
(500 mg/ml). Either molecules strongly inhibited cell proliferation (** p,0.01 vs FGF-2). (B) Representative images of experiments depicted in panel A
are reported (scale bar=25 mm). (C) SK-MEL-110 apoptosis was quantified as percentage of cells in sub-G1 phase, by FACS analysis of PI-stained cells
after 48 h RGDS or RAM treatment (500 mg/ml) (* p,0.05 vs FGF-2 and ** p,0.01 vs FGF-2, respectively). Three independent experiments were
performed and quantified and mean 6 S.D. is reported; one representative experiment is shown (right side).
doi:10.1371/journal.pone.0025352.g003
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caspase 3 cleavage and survivin expression after RGDS and RAM treatment, in collagen IV seeded cells. (B) Apoptosis was also visualized by TUNEL
staining and by nuclear fragmentation (Hoechst staining). Nuclei stained with Hoechst as well as TUNEL-positive nuclei were identified by means of a
Zeiss Axioplan fluorescence microscope (original magnification, 640).
doi:10.1371/journal.pone.0025352.g004
Figure 5. Stability test carried out in serum, in adhesion-dependent assays. (A) (Top) RGDS and RAM stability in serum was evaluated in a
proliferation assay onto plastic-seeded cells. The molecules were either tested immediately after thawing (fresh molecules) or tested after 24 h pre-
incubation at 37uC in 100% FCS (aged molecules). Under these conditions, RGDS (500 mg/ml) lost anti-proliferation activity compared to fresh RGDS
(RGDS black vs RGDS white column), while RAM (500 mg/ml) maintained the ability to inhibit melanoma cells proliferation (RAM black vs RAM white
column) (** p,0.01 vs FCS). In addition RAM aged molecule showed a significant higher anti-proliferation activity as compared to RGDS aged
molecule (* p,0.05 RAM vs RGDS). Three independent experiments were performed and mean 6 S.D. is reported. (Bottom) Representative images of
treated cells are reported (scale bar=25 mm). (B) RGDS and RAM were pre-incubated in 100% FCS at 37uC for increasing time points (0.5-1-24-48
hours) and then used in adhesion assay. Under these conditions, RAM significantly does not change its anti adhesive effect, while RGDS anti adhesive
action is largely lost at 24 h (* p,0.05 RAM vs FCS).
doi:10.1371/journal.pone.0025352.g005
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collagen IV to allow RGDS- independent adhesion. RGDS, RAM and the control cyclo-RGDS were kept in 100% serum for 24 h in order to allow serum-
induced degradation. Under such conditions RGDS and its analog cyclo-RGDS were inactive or significantly less active than RAM. (B) RGDS and RAM
effect on DNA synthesis and apoptosis onto collagen seeded cells. RGDS and RAM (500 mg/ml) effect on DNA synthesis and apoptosis of melanoma
cells was evaluated by FACS analysis. (a) (Top): DNA synthesis was analyzed by BrdU incorporation after 48 h treatment. While RAM in FCS reduced
DNA synthesis, RGDS had no effect. (Bottom): Three independent experiments were performed and quantified; one representative experiment is
shown (** p,0.01 vs FCS). (b) (Top): Apoptosis was quantified as percentage of sub G1-cell-phase by PI staining using FACS. RAM induced apoptosis
under these experimental conditions, while RGDS had no pro-apoptotic effect (** p,0.01 vs FCS). Three independent experiments were performed
and mean 6 S.D. is reported. (Bottom): One representative experiment is shown.
doi:10.1371/journal.pone.0025352.g006
Figure 7. In vitro proliferation of B16F10 and in vivo experiments. (A) In vitro proliferation of mouse melanoma cell line (B16F10) seeded onto
collagen IV in the presence of serum, was significantly inhibited by RGDS or RAM (500 mg/ml). (* p,0.01 vs FCS). (B) RGDS and RAM were tested in
vivo in a mouse melanoma lung-metastasis model. C57BL6/J mice were treated with B16F10 cells inoculated intravenously to induce lung metastasis
formation. RGDS and RAM (2.6 mM) treatments were carried out according to three different injection schedules: i) at days 9
th and 11
th (2 total
injected doses), ii) at days 7
th,9
th and 11
th (3 total injected doses) and iii) at days 5
th,7
th,9
th 11
th (4 total injected doses. At day 14
th mice were
sacrificed, lungs were isolated and superficial macroscopic lung-metastases were counted. The number of metastatic foci in control mice was 124640
(set to 100%). RAM significantly reduced the number of superficial metastases in a dose-dependent way (* p,0.05 vs control, by ANOVA), while RGDS
was less effective. C) Representative lung-images are reported.
doi:10.1371/journal.pone.0025352.g007
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melanoma cell proliferation by about 40% (Figure 7A). RGDS and
RAM were then tested in vivo at the same molar dose (2.6 mM) in a
mouse melanoma-lung metastasis model, according to procedures
and doses previously identified for other RGD analogs [32].
B16F10 cells were injected at day 0 intravenously in C57BL6/J
male mice (12 mice per group) to induce lung metastasis
formation. Then RGDS and RAM treatments were injected into
vein tail according to three different treatment schedules: i) at days
9
th and 11
th (i.e., 2 total injected doses), ii) at days 7
th,9
th and 11
th
(i.e., 3 total injected doses) and iii) at days 5
th,7
th,9
th 11
th (i.e., 4
total injected doses). One-dose injection had been previously
shown to be not active at all, in preliminary studies (not shown).
According to the schedule followed, treatment was carried out
when metastases were already formed and growing. On day 14
th
mice were sacrificed and superficial macroscopic lung-metastases
were then counted. RAM markedly reduced the number of
superficial metastatic foci in a dose-dependent way reaching a
significant 70%615% inhibition (p,0.05 by ANOVA followed by
Dunnett’s test) at 4 injections schedule. On the contrary, RGDS
showed a stable effect around 50% inhibition, not statistically
significant (p.0.05 by ANOVA followed by Dunnett’s test)
(Figure 7C).
Discussion
The RGD motif occurs in several ECM proteins and is involved
in integrin-mediated cell adhesion, cell survival, invasion, blood
coagulation. RGD-containing peptides are currently used in tumor
imaging, cell-targeting and radio-treatment [2,10,19,33]. We and
Others demonstrated that RGD peptides, besides the extra-
cellular anti adhesive effect, may internalize into different cell-
types, including melanoma and endothelial cells, and recognize
intracellular targets involved in cell-survival [23,24,25,26,34].
According to these findings it is possible to hypothesize, besides the
well recognized extracellular anti adhesive activity, an additional
intracellular role of RGD-containing peptides released from the
extracellular matrix during physiologic and pathologic tissue-
remodeling [35]. Such considerations foster renewed interest on
novel clinical use in pathological conditions. In fact many studies
aim at developing novel RGD non-peptide analogs with increased
efficacy and resistance to proteolytic degradation. RGD peptides
show a short half life and are quickly metabolized in vivo; for this
reason they require high doses to reach acceptable anti metastatic
effects in vivo [13], while low (namely, nanomolar) concentrations
are reported to paradoxically stimulate tumor growth and tumor
angiogenesis, under certain experimental conditions [36]. RGD
containing peptides showing duplication and circularization
[17,18,31], or non-peptidic analogs with higher activity and/or
higher stability in vivo [19,20,21,22] may overcome such limitation,
at least in part. We previously demonstrated that both RGDS and
its novel analog RAM exert biological effects likely un-related to
their anti adhesion activity; in fact they both show strong biological
effects onto collagen IV seeded endothelial cells [23,27]. Collagen
IV is known to mediate cells adhesion requiring mostly RGDS-
independent integrins [1]. While both RGDS and RAM strongly
inhibit cell-adhesion to plastic and vitronectin as well as
angiogenesis in vivo, on the other hand they do not significantly
inhibit endothelial cell adhesion onto collagen IV, and have clear
pro apoptotic effects onto collagen IV–seeded HUVEC. Therefore
we concluded that RGDS and RAM have biological effects onto
endothelial cells dependent and independent from their anti
adhesion activity. A clear anti-melanoma activity of RGDS has
been recently observed, by direct targeting intracellular molecules
involved in the apoptotic cascade, further confirming that RGDS
acts via novel mechanisms, additionally to the known anti adhesive
effects [24]. In the present study we investigated whether RAM
mimics at least in part the effects of RGDS on human metastatic
melanoma cells in vitro as well as in vivo. Figures 1 to 4 of the
present study strongly support the conclusion that RAM is a good
functional RGDS-analog under several experimental conditions.
They were tested in adhesion assays onto several surfaces (namely
plastic, vitronectin, fibronectin, von Willebrand Factor, laminin
and collagen IV showing similar anti adhesion effects onto surfaces
requiring RGD-dependent adhesion, thus indicating similar
specificity for RGD-related integrins. However not exactly
overlapping effects were observed in the assay involving laminin-
integrin receptors (namely a3, a6, a7 integrins) suggesting a
different specificity for these receptors. Several data reported here
indicating common and different effects of RGDS and RAM
support the hypothesis that the two molecules may have common
targets and in part different targets.
Most interestingly, when FCS-induced degradation was al-
lowed, RAM appeared to be significantly more potent that RGDS,
both in plastic-seed and collagen-IV- seed conditions (Figures 5, 6).
The cyclo-RGDS peptide, i.e. a RGDS-analog developed as a
potent anti adhesive molecule [31], was completely inactive under
collagen IV- seed conditions (Figure 6), further confirming that
RAM exerts biological effects unrelated to the anti adhesion
properties, in the presence of serum. Furthermore, such evidence
allowed us to conclude that RAM maintains its effect in the
presence of serum, while RGDS almost completely loses it upon
FCS pre-incubation (Figure 5A–B). RGDS degradation in the
presence of serum is a known phenomenon, and synthesis of non-
peptidic analogs such as RAM is specifically intended to overcome
this limitation and to allow further in vivo investigation, in tumor
and non-tumor animal models. The present study supports the
hypothesis that serum components, likely proteases, may degrade
RGDS, abolishing its potent anti-mitogenic effect evident in vitro in
the absence of serum, while they do not affect RAM activity.
While RAM appears to be more potent than RGDS in the
presence of serum (Figure 5 and Figure 6), the two molecules show
closer efficacy in the presence of FGF-2 in vitro (Figure 4), i.e. in the
absence of serum-induced degradation. Therefore Figures 1 to 6
and Figure S2 suggest that RAM has higher stability and at least
partially different target specificity.
All the above considerations suggest that RAM may be more
potent in vivo as compared to RGDS, indicating RAM as a good
candidate for in vivo applications. A pure anti adhesive action may
be not sufficient to induce regression of metastases already formed;
therefore RAM, due to its serum-degradation resistance and to
adhesion-unrelated properties, was hypothesized to induce metas-
tasis-regression and to show clear anti-tumor activity in an in vivo
model. In a mouse melanoma-lung metastasis model RGDS and
RAM were therefore injected intravenously at similar molar
concentration and increasing doses. RAM strongly and signifi-
cantly reduced in a dose dependent way the number of lung
superficial metastases as compared to controls, while RGDS anti-
metastatic effect was less potent and dose-independent (Figure 7).
These results suggested that RAM and RGDS in vivo anti-
melanoma action may be due to a combined anti adhesive and
non-anti adhesive mechanism and that RAM may have higher
potency due to the higher resistance to FCS-induced degradation.
Other Authors previously tested the effect of RGD-analogs in
mouse melanoma models [37,38,39]. In these studies (differently
from the present study), melanoma cells were co-injected
intravenously with the RGD-analogs, showing a marked inhibition
of lung metastasis achieved by an anti adhesive mechanism, acting
RAM Inhibits Melanoma In Vitro and In Vivo
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other study the potent effect was totally lost by injecting the RGDS
analog onto already formed metastases [4]. This study indicated
once again that pure anti adhesive molecules may show a potent
anti-proliferation effect but may lack activity onto metastases
already formed. Differently from these previous studies, in the
present study treatment was started at least 5 days after cell
inoculation, i.e. when cells are already adhered and metastases are
growing already. Under such conditions RAM exerted a dose-
dependent and significantly more potent effect than RGDS.
Experimental conditions followed in the present study may
therefore better re-capitulate clinical conditions and the collected
data likely indicate novel relevance for possible clinical applica-
tions.
According to a report we published recently [24], RGDS may
induce melanoma apoptosis by directly recognizing intracellular
targets such as pro-caspases and survivin. Figure 4A shows that
RAM and RGDS have similar intracellular effects on pro-caspase-
3 expression and survivin expression. Although further studies are
needed, we hypothesize that RAM may achieve such effects at
least in part by an intracellular activity to be further investigated
with liposome-based formulations aimed at facilitating the
intracellular targeting.
While further histological and toxicological studies are needed,
the present study represents the first demonstration, at our
knowledge, that a RGDS-analog shows marked anti-metastatic
activity in an in vivo model of growing melanoma metastases.
Materials and Methods
Ethics statement
The present study has been carried out in compliance with the
Italian National Direction n. 86/609/CEE, which regulates
animal-care procedures in in vivo experimentations. Experimental
procedures were performed within the protocol deposited
according to Decreto Legislativo 116/92 at the review board of
Universita ` Cattolica del Sacro Cuore, Roma, approved with the
identification number A39B.
Peptide synthesis
RGDS peptide (Arginine-Glycine-Aspartic acid-Serine) and
Cyclo(-Arg-Gly-Asp-D-Phe-Val) (Cyclo-RGDS) were purchased
from Bachem (Bubendorf, Switzerland). RGDS-analogue named
RAM was designed to lack peptide bonds, as previously reported
in detail [27,30] and was synthesized by NeoMPS SA (Strasbourg,
France) with a purity .95%. RAM structure is H2N-Arg-D-Phe-
Arg-Malonyl-Asp-NH2 and is reported in Figure S1. Two separate
preparations have been used throughout this study, showing
similar results.
Cell culture
Human metastatic melanoma cells line SK-MEL-110 were
obtained from Gorospe et al. [40]; mouse lung metastatic B16F10
melanoma cells and human malignant melanoma SK-MEL-28
were from ATCC (Manassas, VA). SK-MEL-110 cells showed the
expected microscopic phenotype and grew as expected in the
presence and in the absence of serum or growth factors. Data
obtained on SK-MEL-110 were validated in vitro and in vivo on
B16F10 mouse melanoma cells and in vitro on SK-MEL-28 human
melanoma cells, both authenticated by ATCC (not shown). Cells
were grown as previously reported [41] in DMEM (Hyclone,
Logan, UT) supplemented with 2 mM L-glutamine, 100 IU/ml
penicillin-streptomycin (Gibco, Invitrogen corporation, Carlsbad,
CA), and 10% heat-inactivated FCS (Hyclone, Logan, UT), at
37uC in a 5% CO2 atmosphere.
Cell adhesion assay
Cell adhesion to ECM glycoproteins or to plastic was quantified
as previously reported [23]. Briefly, SK-MEL-110 cells were
suspended in DMEM plus fresh FCS 10% with serial dilutions of
RGDS or RAM ranging from 0 to 500 mg/ml. In molecular aging
experiments, molecules were pre-incubated for different time
points (0.5, 1, 24, 48 hours) at 37uC in 100% fetal calf serum
before adhesion assay, to test loss of activity. Cells were pre-
incubated with the ‘‘aged’’ molecules at 37uC for 15 minutes and
then seeded (15000 cells per well) at 37uC for one hour in 96 well
plates pre-coated overnight at 4uC with vitronectin, or laminin, or
fibronectin, or von Willebrand Factor or collagen IV (Becton
Dickinson, Bradford, MA) (50 mg/ml diluted in PBS, pH 7.4;
fibronectin 10 mg/ml diluted in PBS, pH 7.4). Adhesion onto
plastic was also tested. Non-adherent cells were discarded by
repeated washes, then adherent cells were fixed with 4%
formaldehyde in PBS, pH 7.4, for 10 minutes at RT and stained
with 0.5% toluidine blue (Merck KgaA, Darmstadt, Germany) in
4% formaldehyde for 10 minutes at RT. Plates were then rinsed
extensively with water and stain was extracted by incubation with
sodium dodecyl sulfate (SDS) 1% in PBS, pH 7.4, for 30 minutes
at RT. Cell adhesion was then quantified as optical density (OD)
at 595 nm.
Proliferation assay, cell cycle analysis and apoptosis
SK-MEL-110 human melanoma cells were assayed as previ-
ously reported [24]. They were plated in 6 well plates (8610
4
cells/well) onto plastic or onto collagen IV (50 mg/ml) and were
allowed to grow for 24 h in DMEM 10% FCS at 37uC. Medium
was then replaced with DMEM serum-free for 24 h. Subsequent-
ly, cells were exposed to RGDS or RAM dissolved in complete
medium or in DMEM containing FGF-2 (Pierce Endogen,
Rockford, USA), for 24 h or 48 h at 37uC. Then, cells were
photographed, harvested by trypsin-EDTA and counted using
hemacytometer. All experiments were carried out at least 3 times
in duplicate.
Additional proliferation experiments were carried out with the
specific aim to test RGDS, RAM and cyclo-RGDS stability in the
presence of serum; SK-MEL-110 cells were exposed for 24 h to
RGDS or RAM or cyclo-RGDS (500 mg/ml) pre-incubated for
24 h at 37uC in 100% fetal calf serum (FCS).
The effect of RAM and RGDS on DNA synthesis was
performed by combination of bromodeoxyuridine (BrdU) and
propidium iodide staining. Treated SK-MEL-110 were incubated
for the last 30 minutes with 20 mmol/L BrdU (Sigma) and then
fixed with 70% ethanol, according to a previously reported
procedure [42].
In cell cycle studies, SK-MEL-110 human melanoma cells were
plated in 6 well plates (8610
4 cells/well) onto collagen IV (50 mg/
ml) and were allowed to grow for 24 h in DMEM 10% FCS at
37uC. To synchronize SK-MEL-110, exponentially growing cells
were treated with DMEM 10% FCS containing 100 ng/ml
nocodazole (Sigma), for 16 h and then released, as needed, into
drug-free medium. The nocodazole mother solution was dissolved
in dimethyl sulfoxide (DMSO) stored at 220uC. Control cultures
received an equivalent amount of DMSO. After 16 h medium was
replaced with fresh DMEM 10% FCS containing RGDS or RAM
and cell were treated for 6 h and 24 h. Cells then were harvested
by trypsin-EDTA, fixed in ice-cold 70% ethanol and stained with
propidium iodide at final concentration of 10 mg/ml [24]. Cell
cycle analysis was performed by propidium iodide staining using a
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software for quantification of PI-positive cells [42]. FACS
measurements were performed on three independent synchroni-
zation experiments.
Apoptosis was assayed on cells seeded onto collagen IV, by
analyzing sub-G1 phase and by TUNEL assay (terminal
deoxynucleotidyl transferase-mediated dUTP nick end-labeling)
and nuclear staining with the DNA-binding fluorochrome Hoechst
33258 (1 mg/ml) (Sigma) [23]. Nuclei were examined with an
Axioplan 2 microscope (Zeiss). The number of apoptotic nuclei
was determined by counting 10 different fields (4006 magnifica-
tion) per sample.
Cell Invasion
FCS 10%–induced melanoma cells invasion was measured in
modified Boyden chambers as previously reported [23]. Briefly, 8-
mm pore-size polycarbonate filters (Costar, Cambridge, MA) were
coated with murine collagen type IV (10 mg/ml) for one hour.
Growing SK-MEL-110 were harvested by trypsinization, re-
suspended in DMEM 0.1% BSA, and 200 mL was added to the
upper portion of the chambers at 1610
6 cells/ml in the presence
of RGDS or RAM (500 mg/ml); the lower portion of the Boyden
chamber contained complete medium as chemoattractant. After
4 hours at 37uC, cells were fixed in 95% ethanol and stained with
Giemsa (Merck KGaA, Darmstadt, Germany) for 10 minutes.
The number of migrated cells was evaluated by counting 15 fields
at 6400 magnification.
Western blotting
SK-MEL-110 seeded on collagen IV and treated for 48 h with
FGF-2 in the presence of RGDS or RAM (500 mg/ml), were lysed
with RIPA buffer [23]. Samples were boiled, loaded and separated
by SDS-PAGE and transferred to nitrocellulose membrane.
Membrane was blocked with 5% milk (Bio-Rad Laboratories) in
TPBS (0.1% Tween 20 in PBS, pH 7.4), washed and incubated
with mouse anti-survivin (1:200) (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-caspase 3 (1:200) (Santa Cruz Biotechnol-
ogy, Alexa, CA,), or mouse anti-b-actin (1:5000) (Sigma-Aldrich,
St Louis, MO) in milk 5% TPBS 0.1% for 1 h at RT. Horseradish
peroxidase-conjugated secondary antibodies (Pierce) were used,
followed by chemiluminescence assay (ECL; Amersham, Buck-
inghamshire, United Kingdom) and autoradiography.
In vivo experiments for lung metastasis
In vivo experiments for lung metastasis were performed
according to an accepted animal-study protocol. Three months-
old male C57BL6/J mice (12 mice per group) (Charles River,
Wilmington, MA) received an i.v. injection of B16F10 cells
(2610
5/200 ml in PBS) into the tail vein for experimental
metastasis studies at day 0 [43]. Mice were then treated according
to a modified schedule derived from the literature [32] with some
modification, receiving repeated i.v. injections of 200 mlo f
identical molar doses of RGDS or RAM (2.6 mM in PBS)
(corresponding to 1.25 mg/ml/dose RGDS and 1.8 mg/ml/dose
RAM, corresponding to 8 mg/kg/dose and 12 mg/Kg/dose,
respectively). RGDS and RAM treatments were carried out
according to three different schedules: i) injection at days 9
th and
11
th (2 total injected doses), ii) injection at days 7
th,9
th and 11
th (3
total injected doses) and iii) injection at days 5
th,7
th,9
th 11
th (4
total injected doses These schedules were chosen to start treating
mice 5, 7 and 9 days after cell inoculations respectively, i.e. when
lung metastases are already developing, in order to study
metastases-regression, rather than cell-adhesion to the lung tissue.
Mice were sacrificed at day 14
th and lung-superficial macro-
scopic metastases were counted using a magnifying glass (206).
Statistical analysis
All in vitro and in vivo efficacy experiments were performed at
least three times in duplicates. Student’s t test was carried out in
most cases. To analyze in vivo effects, one-way ANOVA test
followed by Dunnett’s Multiple Comparison Test as post-hoc
analysis were carried out with PRISM software; p,0.05 was
considered the statistically significant threshold.
Supporting Information
Figure S1 RAM molecular structure.
(TIF)
Figure S2 The in vitro anti proliferation effect of RGDS
and RAM (500 mg/ml) on collagen IV was investigated in
the presence of FCS in SK-MEL-28 human melanoma
cell line. RAM shows a significant anti proliferative action, while
RGDS is inactive. Onto SK-MEL-110 human melanoma cell line
RGDS has a weak effect while RAM has strong inhibitory effect
(see Fig. 2D).
(TIF)
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